19. Trulicity

Trulicity is currently holding its own in sales despite competition. (Eli Lilly)

Company: Eli Lilly
2019 sales: $4.13 billion 
Projected 2026 sales: $7.43 billion 
Projected CAGR: +9%
Used for: glycemic control for Type 2 diabetes

Eli Lilly's GLP-1 diabetes fighter Trulicity has been locked in a battle for sales supremacy with Novo Nordisk's Ozempic and oral follow-up drug Rybelsus. But with a recent first-of-its-kind approval in tow, Trulicity could be well positioned to keep adding to its blockbuster sales in the coming years despite the pressure. 

Trulicity snagged $4.13 billion in 2019 sales in its fifth year on the market. With a new cardiovascular risk reduction label expansion, the drug could be set to reach $7.43 billion in sales in 2026, Evaluate Pharma predicted. 

That new CV approval could prove to be a gamechanger not only for Trulicity but also the rest of the GLP-1 class, including the fierce rivals from Novo.

RELATED: Eli Lilly's Trulicity nabs novel CV approval in patients with or without established disease

19. Trulicity